Nephros Inc (NEPH)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
$4.52+3.67%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
Intact: The reason to own it still holds.
Nephros reached $5.2 million revenue in 2026-Q1, hitting its goal. Analysts expect about 14% revenue growth next year. The company is profitable with a clear growth path. Its water solutions have steady demand in medical markets.
Nephros trades at a high price-to-earnings ratio of 50. Profit margins could stay fragile. Revenue growth might slow below analyst expectations.
The price is about 28% above our fair value near $2.79. The market expects 14% revenue growth, which matches analyst views.
Breaks if: profit margins decline significantly below recent levels
Breaks if: quarterly revenue falls below $5 million in any quarter
Nephros aims to consistently achieve and exceed $5 million in quarterly revenue.
Breaks if: annual revenue growth falls below 7% in FY26
Nephros aims to consistently achieve and exceed $5 million in quarterly revenue.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
NEPH is a speculative growth investment, as it is currently loss-making but has shown strong revenue growth. The current thesis state is intact, supported by recent earnings performance.
The market seems to have a stretched valuation, with expectations that may not fully account for potential risks. There is a medium confidence in the model, indicating that some uncertainty surrounds future performance.
Management is focused on achieving revenue growth and expanding core revenue streams, which have shown positive results. However, there are mixed signals regarding managing gross margin pressures, which could impact future performance.
The long-term thesis hinges on NEPH's ability to maintain revenue growth while navigating potential risks from economic conditions and sector performance. Key triggers include guidance changes and the performance of sector bellwethers.
Over the next 1 to 3 years, NEPH's prospects will depend on its management execution and external economic factors. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats to the thesis at this time.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.